Trade LTRN stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Lantern Pharma Inc. (LTRN) is trading at US$1.50, down 3.23% today as of Sep 21, 16:00 EDT. The company has a market capitalisation of US$29.91M. Over the past 52 weeks, LTRN has traded between US$1.11 and US$4.70. On Syfe you can trade LTRN with $0 commission and add it to your watchlist.
| Previous close | US$1.55 |
|---|---|
| Market cap | US$29.91M |
| 52-week range | US$1.11 – US$4.70 |
| Volume | 246.48K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Lantern Pharma Inc.
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.
Year: 2020
Lantern Pharma Says Zirdafulven Phase 1b/2 Trial in Bladder Cancer Cleared by European Medicines Agency
Jul 28, 12:35 PM · MT Newswires
Lantern Pharma Receives US Patent Allowance for Cancer Drug LP-184
Jul 23, 12:57 PM · MT Newswires
Lantern Pharma Says Longer LP-300 Treatment Helped Lung Cancer Patients in Phase 2 Study
Jun 2, 12:50 PM · MT Newswires
Lantern Pharma Inc. (LTRN) stock is trading at US$1.50, -3.23% from the previous close of US$1.55.
The market cap for Lantern Pharma Inc. (LTRN) stock is approximately US$29.91M.
The 52-week high for Lantern Pharma Inc. (LTRN) stock is US$4.70.
The 52-week low for Lantern Pharma Inc. (LTRN) stock is US$1.11.
Lantern Pharma Inc. (LTRN) does not currently pay a dividend.
Stay on top of LTRN
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
